Skip to main content
Clinical Trials/NCT05152667
NCT05152667
Unknown
N/A

Ambispective Comparative Cohort Study to Assess the Effect of Pretreatment With a Levonorgestrel-Releasing Intrauterine System Versus Oral Progestin on ICSI and Vitrified-Warmed Embryo Transfer Outcomes in Women With Adenomyosis

Wael Elbanna Clinic1 site in 1 country354 target enrollmentNovember 27, 2021
ConditionsAdenomyosisIVF

Overview

Phase
N/A
Intervention
Not specified
Conditions
Adenomyosis
Sponsor
Wael Elbanna Clinic
Enrollment
354
Locations
1
Primary Endpoint
ongoing pregnancy
Last Updated
4 years ago

Overview

Brief Summary

The study participants' relevant medical records will be collected and reviewed for the retrospective subjects and after obtaining informed consent for the prospective subjects. The study materials that will be used will include blood tests, transvaginal ultrasound and magnetic resonance imaging (MRI). The study will involve two study arms

Detailed Description

The study participants' relevant medical records will be collected and reviewed for the retrospective subjects and after obtaining informed consent for the prospective subjects. The study materials that will be used will include blood tests, transvaginal ultrasound and magnetic resonance imaging (MRI). The study will involve two study arms: Arm 1: Women with adenomyosis pretreated with levonorgestrel-releasing intrauterine device (LNG-IUS) and proceeding with the ICSI Arm 2: Women with adenomyosis pretreated with oral progestin "Dienogest" and proceeding with the ICSI Primary and secondary key measurements will be used in the study. The primary measures will include: * Presence of intrauterine gestational sac at 12 weeks * Presence of fetal heart pulsation at 12 weeks The secondary key measures will include: * Occurance of abortion in the 1st trimester * Appearance of ectopic pregnancy diagnosis by: Ultrasound Serum β-HCG level Symptoms of pain and bleeding * Two serum β-HCG levels in 48hrs interval to emphasis biochemical pregnancy * Recording the the baseline characteristics of the study participants

Registry
clinicaltrials.gov
Start Date
November 27, 2021
End Date
July 2022
Last Updated
4 years ago
Study Type
Observational
Sex
Female

Investigators

Sponsor
Wael Elbanna Clinic
Responsible Party
Principal Investigator
Principal Investigator

Wael Elbanna

Managing director for Wael Elbanna Clinic

Wael Elbanna Clinic

Eligibility Criteria

Inclusion Criteria

  • Patients diagnosed using both the transvaginal ultrasound study (TVS) and MRI criteria
  • Main criteria for sonographic and MRI diagnosis of adenomyosis are:
  • The appearance of asymmetrical thickening of the myometrium Irregular cystic areas within the myometrium Linear striations radiating out from the myometrium
  • Patients ≤42 years old at the time of starting ICSI cycle
  • Cryopreserved embryo transfer cycles
  • The presence of at least one good cryopreserved day 3 embryo.

Exclusion Criteria

  • Transfer of a poor-quality embryo (grades 3 or 4)
  • History of myomectomy
  • Pelvic ultrasound that showed the presence of uterine fibroids, a hydrosalpinx or endometrial polyps (all known causes of implantation failure).

Outcomes

Primary Outcomes

ongoing pregnancy

Time Frame: up to 13 weeks gestation

- Recording the following for the two arms of the study: Presence of intrauterine gestational sac at 12 weeks Presence of fetal heart pulsation at 12 weeks

Secondary Outcomes

  • Recording the baseline characteristics of the study participants(Before study intervention)
  • Occurance of abortion or ectopic(up to 13 weeks gestation)

Study Sites (1)

Loading locations...

Similar Trials